Tags

Type your tag names separated by a space and hit enter

Association of Helicobacter pylori with Parkinson's Disease.
J Clin Neurol. 2017 04; 13(2):181-186.JC

Abstract

BACKGROUND AND PURPOSE

Parkinson's disease (PD) is a major neurological disorder that requires lifelong treatment, and the combined presence of Helicobacter pylori (H. pylori) infection can increase the required anti-PD medications. We aim to investigate the effect of H. pylori infection in Indian PD patients.

METHODS

We prospectively recruited 36 PD patients from December 2007 to January 2011. All patients underwent a detailed neurological evaluation and serological examination for H. pylori infection. Seropositive and seronegative patients were considered to be the cases and controls, respectively. All patients who were seropositive received triple therapy for 2 weeks. Outcome measures of the mean 'off' Unified Parkinson's Disease Rating Scale (UPDRS)-III score, mean 'on' UPDRS-III score, mean onset time, mean 'on' duration, and mean daily 'on' time were measured at baseline and at a 3-week follow-up.

RESULTS

H. pylori-IgG positivity was present in 18 (50%) PD patients. The prevalence of men (72.2% vs. 33.3%), mean duration of disease (13.8 vs. 12.5) and mean levodopa equivalent daily dose (824 mg vs. 707 mg) were significantly higher among H. pylori positive patients than in controls (p<0.0001). Controls had a significantly longer 'on' duration and daily 'on' time, and better 'on' UPDRS-III scores. Seropositive patients took a significantly longer time to turn 'on' after a levodopa challenge. At the 3-week follow-up, H. pylori eradication significantly improved the mean 'on' UPDRS-III score, onset time, 'on' duration, and daily 'on' time.

CONCLUSIONS

H. pylori infection was present in 50% of Indian PD patients. H. pylori seropositivity was associated with a poor response to levodopa and increased medication usage, while eradication therapy was associated with better patient outcomes.

Authors+Show Affiliations

Department of Neurology, Nizam's Institute of Medical Sciences, Hyderabad, India. rukminimridula@gmail.com.Department of Neurology, Nizam's Institute of Medical Sciences, Hyderabad, India.Department of Neurology, Nizamabad Neuro Super Specialty Hospital, Nizamabad, India.Department of Clinical Research & Neurology, Yashoda Hospitals, Hyderabad, India.Department of Neurology, Nizam's Institute of Medical Sciences, Hyderabad, India.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28406585

Citation

Mridula, Kandadai Rukmini, et al. "Association of Helicobacter Pylori With Parkinson's Disease." Journal of Clinical Neurology (Seoul, Korea), vol. 13, no. 2, 2017, pp. 181-186.
Mridula KR, Borgohain R, Chandrasekhar Reddy V, et al. Association of Helicobacter pylori with Parkinson's Disease. J Clin Neurol. 2017;13(2):181-186.
Mridula, K. R., Borgohain, R., Chandrasekhar Reddy, V., Bandaru, V. C. h., & Suryaprabha, T. (2017). Association of Helicobacter pylori with Parkinson's Disease. Journal of Clinical Neurology (Seoul, Korea), 13(2), 181-186. https://doi.org/10.3988/jcn.2017.13.2.181
Mridula KR, et al. Association of Helicobacter Pylori With Parkinson's Disease. J Clin Neurol. 2017;13(2):181-186. PubMed PMID: 28406585.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Association of Helicobacter pylori with Parkinson's Disease. AU - Mridula,Kandadai Rukmini, AU - Borgohain,Rupam, AU - Chandrasekhar Reddy,Vupparalli, AU - Bandaru,Venkata Chandrasekhar Srinivasarao, AU - Suryaprabha,Turaga, PY - 2016/11/14/received PY - 2017/01/02/revised PY - 2017/01/05/accepted PY - 2017/4/14/entrez PY - 2017/4/14/pubmed PY - 2017/4/14/medline KW - H. pylori infection KW - Indian patients KW - Parkinson's disease KW - prevalence KW - triple therapy SP - 181 EP - 186 JF - Journal of clinical neurology (Seoul, Korea) JO - J Clin Neurol VL - 13 IS - 2 N2 - BACKGROUND AND PURPOSE: Parkinson's disease (PD) is a major neurological disorder that requires lifelong treatment, and the combined presence of Helicobacter pylori (H. pylori) infection can increase the required anti-PD medications. We aim to investigate the effect of H. pylori infection in Indian PD patients. METHODS: We prospectively recruited 36 PD patients from December 2007 to January 2011. All patients underwent a detailed neurological evaluation and serological examination for H. pylori infection. Seropositive and seronegative patients were considered to be the cases and controls, respectively. All patients who were seropositive received triple therapy for 2 weeks. Outcome measures of the mean 'off' Unified Parkinson's Disease Rating Scale (UPDRS)-III score, mean 'on' UPDRS-III score, mean onset time, mean 'on' duration, and mean daily 'on' time were measured at baseline and at a 3-week follow-up. RESULTS: H. pylori-IgG positivity was present in 18 (50%) PD patients. The prevalence of men (72.2% vs. 33.3%), mean duration of disease (13.8 vs. 12.5) and mean levodopa equivalent daily dose (824 mg vs. 707 mg) were significantly higher among H. pylori positive patients than in controls (p<0.0001). Controls had a significantly longer 'on' duration and daily 'on' time, and better 'on' UPDRS-III scores. Seropositive patients took a significantly longer time to turn 'on' after a levodopa challenge. At the 3-week follow-up, H. pylori eradication significantly improved the mean 'on' UPDRS-III score, onset time, 'on' duration, and daily 'on' time. CONCLUSIONS: H. pylori infection was present in 50% of Indian PD patients. H. pylori seropositivity was associated with a poor response to levodopa and increased medication usage, while eradication therapy was associated with better patient outcomes. SN - 1738-6586 UR - https://www.unboundmedicine.com/medline/citation/28406585/Association_of_Helicobacter_pylori_with_Parkinson's_Disease_ L2 - https://thejcn.com/DOIx.php?id=10.3988/jcn.2017.13.2.181 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.